In vitro chemosensitivity of human lung cancer cell lines.

J. C. Ruckdeschel, D. N. Carney, H. K. Oie, E. K. Russell, A. F. Gazdar

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Human lung cancer cell lines, established from patients with both small cell cancer (SCLC) and non-small cell cancer (non-SCLC; squamous cell, large cell, anaplastic, and adenocarcinoma), were tested for their in vitro chemosensitivity to a panel of drugs. Drug sensitivity was assayed by either soft agar clonogenicity or a novel dye-exclusion assay. Eleven non-SCLC lines (eight continuous, three recently cultured) and five SCLC lines (all continuous) were tested. Four of eight continuous non-SCLC lines cloned sufficiently to permit limited in vitro drug testing, as did two of the five SCLC lines. All 16 cell lines could be tested for multiple drugs using the dye-exclusion assay. Drug concentrations for the nonclonogenic assay more closely approximated the area under the concentration-time curve for a given concentration of each agent. There was considerable variation in the relative sensitivity of the cell lines and the patterns of individual drug sensitivity. The majority of non-SCLC cell lines were refractory to most drugs. Cell lines derived from two previously treated SCLC patients and from three untreated SCLC patients showed greater sensitivity. Concurrent clonogenic and dye-exclusion assays showed similar drug rankings but different absolute values for percent survival. The nonclonogenic dye-exclusion assay is more rapid than the soft agar clonogenic assay (4 days vs. 2-3 weeks), could be performed on all cell lines tested, and appears to reflect the clinical diversity of human lung cancer.

Original languageEnglish (US)
Pages (from-to)697-704
Number of pages8
JournalCancer Treatment Reports
Volume71
Issue number7-8
StatePublished - Jul 1987

Fingerprint

Lung Neoplasms
Cell Line
Pharmaceutical Preparations
Neoplasms
Coloring Agents
Squamous Cell Neoplasms
Agar
In Vitro Techniques
Adenocarcinoma
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ruckdeschel, J. C., Carney, D. N., Oie, H. K., Russell, E. K., & Gazdar, A. F. (1987). In vitro chemosensitivity of human lung cancer cell lines. Cancer Treatment Reports, 71(7-8), 697-704.

In vitro chemosensitivity of human lung cancer cell lines. / Ruckdeschel, J. C.; Carney, D. N.; Oie, H. K.; Russell, E. K.; Gazdar, A. F.

In: Cancer Treatment Reports, Vol. 71, No. 7-8, 07.1987, p. 697-704.

Research output: Contribution to journalArticle

Ruckdeschel, JC, Carney, DN, Oie, HK, Russell, EK & Gazdar, AF 1987, 'In vitro chemosensitivity of human lung cancer cell lines.', Cancer Treatment Reports, vol. 71, no. 7-8, pp. 697-704.
Ruckdeschel JC, Carney DN, Oie HK, Russell EK, Gazdar AF. In vitro chemosensitivity of human lung cancer cell lines. Cancer Treatment Reports. 1987 Jul;71(7-8):697-704.
Ruckdeschel, J. C. ; Carney, D. N. ; Oie, H. K. ; Russell, E. K. ; Gazdar, A. F. / In vitro chemosensitivity of human lung cancer cell lines. In: Cancer Treatment Reports. 1987 ; Vol. 71, No. 7-8. pp. 697-704.
@article{b98415d577bf46b2a1c6c5f162cc8316,
title = "In vitro chemosensitivity of human lung cancer cell lines.",
abstract = "Human lung cancer cell lines, established from patients with both small cell cancer (SCLC) and non-small cell cancer (non-SCLC; squamous cell, large cell, anaplastic, and adenocarcinoma), were tested for their in vitro chemosensitivity to a panel of drugs. Drug sensitivity was assayed by either soft agar clonogenicity or a novel dye-exclusion assay. Eleven non-SCLC lines (eight continuous, three recently cultured) and five SCLC lines (all continuous) were tested. Four of eight continuous non-SCLC lines cloned sufficiently to permit limited in vitro drug testing, as did two of the five SCLC lines. All 16 cell lines could be tested for multiple drugs using the dye-exclusion assay. Drug concentrations for the nonclonogenic assay more closely approximated the area under the concentration-time curve for a given concentration of each agent. There was considerable variation in the relative sensitivity of the cell lines and the patterns of individual drug sensitivity. The majority of non-SCLC cell lines were refractory to most drugs. Cell lines derived from two previously treated SCLC patients and from three untreated SCLC patients showed greater sensitivity. Concurrent clonogenic and dye-exclusion assays showed similar drug rankings but different absolute values for percent survival. The nonclonogenic dye-exclusion assay is more rapid than the soft agar clonogenic assay (4 days vs. 2-3 weeks), could be performed on all cell lines tested, and appears to reflect the clinical diversity of human lung cancer.",
author = "Ruckdeschel, {J. C.} and Carney, {D. N.} and Oie, {H. K.} and Russell, {E. K.} and Gazdar, {A. F.}",
year = "1987",
month = "7",
language = "English (US)",
volume = "71",
pages = "697--704",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7-8",

}

TY - JOUR

T1 - In vitro chemosensitivity of human lung cancer cell lines.

AU - Ruckdeschel, J. C.

AU - Carney, D. N.

AU - Oie, H. K.

AU - Russell, E. K.

AU - Gazdar, A. F.

PY - 1987/7

Y1 - 1987/7

N2 - Human lung cancer cell lines, established from patients with both small cell cancer (SCLC) and non-small cell cancer (non-SCLC; squamous cell, large cell, anaplastic, and adenocarcinoma), were tested for their in vitro chemosensitivity to a panel of drugs. Drug sensitivity was assayed by either soft agar clonogenicity or a novel dye-exclusion assay. Eleven non-SCLC lines (eight continuous, three recently cultured) and five SCLC lines (all continuous) were tested. Four of eight continuous non-SCLC lines cloned sufficiently to permit limited in vitro drug testing, as did two of the five SCLC lines. All 16 cell lines could be tested for multiple drugs using the dye-exclusion assay. Drug concentrations for the nonclonogenic assay more closely approximated the area under the concentration-time curve for a given concentration of each agent. There was considerable variation in the relative sensitivity of the cell lines and the patterns of individual drug sensitivity. The majority of non-SCLC cell lines were refractory to most drugs. Cell lines derived from two previously treated SCLC patients and from three untreated SCLC patients showed greater sensitivity. Concurrent clonogenic and dye-exclusion assays showed similar drug rankings but different absolute values for percent survival. The nonclonogenic dye-exclusion assay is more rapid than the soft agar clonogenic assay (4 days vs. 2-3 weeks), could be performed on all cell lines tested, and appears to reflect the clinical diversity of human lung cancer.

AB - Human lung cancer cell lines, established from patients with both small cell cancer (SCLC) and non-small cell cancer (non-SCLC; squamous cell, large cell, anaplastic, and adenocarcinoma), were tested for their in vitro chemosensitivity to a panel of drugs. Drug sensitivity was assayed by either soft agar clonogenicity or a novel dye-exclusion assay. Eleven non-SCLC lines (eight continuous, three recently cultured) and five SCLC lines (all continuous) were tested. Four of eight continuous non-SCLC lines cloned sufficiently to permit limited in vitro drug testing, as did two of the five SCLC lines. All 16 cell lines could be tested for multiple drugs using the dye-exclusion assay. Drug concentrations for the nonclonogenic assay more closely approximated the area under the concentration-time curve for a given concentration of each agent. There was considerable variation in the relative sensitivity of the cell lines and the patterns of individual drug sensitivity. The majority of non-SCLC cell lines were refractory to most drugs. Cell lines derived from two previously treated SCLC patients and from three untreated SCLC patients showed greater sensitivity. Concurrent clonogenic and dye-exclusion assays showed similar drug rankings but different absolute values for percent survival. The nonclonogenic dye-exclusion assay is more rapid than the soft agar clonogenic assay (4 days vs. 2-3 weeks), could be performed on all cell lines tested, and appears to reflect the clinical diversity of human lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023371141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023371141&partnerID=8YFLogxK

M3 - Article

C2 - 3038314

AN - SCOPUS:0023371141

VL - 71

SP - 697

EP - 704

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7-8

ER -